| Lithium-ion batteries and beyond: Celebrating the 2019 Nobel Prize in chemistry–a virtual issue PV Kamat ACS Energy Letters 4 (11), 2757-2759, 2019 | 86 | 2019 |
| Why Substitution Enhances the Reactivity of LiFePO4 F Omenya, NA Chernova, R Zhang, J Fang, Y Huang, F Cohen, ... Chemistry of Materials 25 (1), 85-89, 2013 | 78 | 2013 |
| Efficacy and tolerability of calcitonin gene–related peptide–targeted monoclonal antibody medications as add-on therapy to onabotulinumtoxina in patients with chronic migraine F Cohen, C Armand, RB Lipton, S Vollbracht Pain Medicine 22 (8), 1857-1863, 2021 | 41 | 2021 |
| Calcitonin gene-related peptide (CGRP)-targeted monoclonal antibodies and antagonists in migraine: current evidence and rationale F Cohen, H Yuan, SD Silberstein BioDrugs 36 (3), 341-358, 2022 | 27 | 2022 |
| The arrival of anti-CGRP monoclonal antibodies in migraine F Cohen, H Yuan, EMG DePoy, SD Silberstein Neurotherapeutics 19 (3), 922-930, 2022 | 20 | 2022 |
| The role of artificial intelligence in headache medicine: Potential and peril. F Cohen Headache: The Journal of Head & Face Pain 63 (5), 2023 | 11 | 2023 |
| Role of atogepant in the treatment of episodic migraines: clinical perspectives and considerations F Cohen, H Yuan Therapeutics and Clinical Risk Management, 447-456, 2022 | 6 | 2022 |
| Efficacy and tolerability of CGRP monoclonal antibody medications in patients with chronic migraine undergoing treatment with onabotulinumtoxinA F Cohen, CE Armand, SE Vollbracht Headache 60, 13-13, 2020 | 5 | 2020 |
| From diet to disasters, lifestyle factors can affect headaches and migraine F Cohen, S Bobker Headache: The Journal of Head and Face Pain 63 (6), 712-713, 2023 | 4 | 2023 |
| Real-world effectiveness of add-on fremanezumab in patients receiving onabotulinumtoxinA for chronic migraine in a US tertiary headache center F Cohen, H Yuan, K Dent, M Beucherie, W Connolly, M Driessen, ... CEPHALALGIA 42 (1_ SUPPL), 127-128, 2022 | 3 | 2022 |
| A randomized study of IV prochlorperazine plus diphenhydramine versus IV hydromorphone for migraine‐associated symptoms: A post hoc analysis F Cohen, BW Friedman Headache: The Journal of Head and Face Pain 61 (8), 1227-1233, 2021 | 2 | 2021 |
| Abstract WP329: Video conferencing is the preferred method for follow-up communication for post-hospital stroke patients F Cohen, J McCarthy, M Gribko, JM Katz, P Wright Stroke 47 (suppl_1), AWP329-AWP329, 2016 | 2 | 2016 |
| Caution regarding fabricated citations from artificial intelligence F Cohen, J Vallimont, AA Gelfand Headache: The Journal of Head and Face Pain 64 (1), 3-4, 2024 | 1 | 2024 |
| Indeterminate serotonin release assays are associated with a high mortality rate S Jindal, C Leyton, F Cohen, M Reyes Gil, H Billett Research and Practice in Thrombosis and Haemostasis 6 (4), e12667, 2022 | 1 | 2022 |
| Migraine prevalence has remained stable while disability has increased in US population studies F Cohen, C Brooks, DM Sun, ML Reed, DC Buse, RB Lipton Headache 62, 33-34, 2022 | 1 | 2022 |
| Prevalence and burden of migraine in the United States: A systematic review F Cohen, CV Brooks, D Sun, DC Buse, ML Reed, KM Fanning, RB Lipton Headache: The Journal of Head and Face Pain, 2024 | | 2024 |
| Artificial intelligence and social media:(Appropriately) harnessing headache medicine's new arsenal in the 21st century. F Cohen, S Bobker Headache, 2024 | | 2024 |
| Real-world effectiveness of add-on fremanezumab in patients receiving onabotulinumtoxinA for the prevention of chronic migraine in a US tertiary headache center: A … H Yuan, F Cohen, MT Driessen, LJ Krasenbaum, M Ortega, M Hopkins, ... Cephalalgia Reports 7, 25158163241238448, 2024 | | 2024 |
| Unraveling the MSG-Headache Controversy: an Updated Literature Review E Ahdoot, F Cohen Current Pain and Headache Reports, 1-6, 2023 | | 2023 |
| AI-Powered Patient Advocacy: Amplifying Health Care Voices MD Cohen MJH Life Sciences, 2023 | | 2023 |
Stanley WhittinghamDistinguished Professor of Chemistry and MaterialsVerified email at binghamton.edu
